Tara L. DuPont
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tara L. DuPont has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Kristin Brinker
Primary Children’s Hospital, Intermountain Health, Salt Lake City, USA
3 shared publications- Timothy M. Bahr
University of Utah
3 shared publications Allison Fisher
Department of Pediatrics, Division of Neonatology, University of Utah, Salt Lake City, USA
2 shared publications- Audrey N. Miller
Nationwide Children’s Hospital, Columbus, USA
2 shared publications Brianna K. Brei
Children’s Nebraska and University of Nebraska Medical Center, Omaha, USA
2 shared publicationsCon Yee Ling
Department of Pediatrics, Division of Neonatology, University of Utah, Salt Lake City, USA
2 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-3
Neurodevelopmental therapy in NICUs that care for infants with bronchopulmonary dysplasia
- 15 September 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-3
Open AccessNeurodevelopmental therapy in NICUs that care for infants with bronchopulmonary dysplasia
- Open Access
- 20 July 2026
- Published by Springer Nature in Research Square
Neuroactive Medication Exposure Across Neonatal Intensive Care Units of a Large, Multistate Healthcare System
Objective To characterize prescribing practices and predictors of neuroactive medication exposure in NICU patients. Study Design This was a retrospective cohort study of 16 968 infants receiving care in five NICUs over six years. We summarized infant exposure to opioids, sedatives, or psychotropics, and evaluated factors that predicted medication exposure and drug exposure patterns over time. Result Of the 17 159 infants admitted to a NICU, 3 032 (18%) were exposed to at least one drug of interest. Lower gestational age (aOR 0.82 per week, 95% CI 0.81–0.83) and White race (aOR 1.28, 95% CI 1.18–1.39) were associated with exposure (both p < 0.001). The rates of dexmedetomidine, ketamine, clonidine, and fentanyl exposure increased over time. Lorazepam, midazolam, and pentobarbital rates decreased. Conclusion Neuroactive medication use has changed over time. Exposure is most common in premature infants, underscoring the urgent need for clinical trials to establish their safety and efficacy.
- 20 July 2026
- Published by Springer Nature in Research Square
Open AccessNeuroactive Medication Exposure Across Neonatal Intensive Care Units of a Large, Multistate Healthcare System
Objective To characterize prescribing practices and predictors of neuroactive medication exposure in NICU patients. Study Design This was a retrospective cohort study of 16 968 infants receiving care in five NICUs over six years. We summarized infant exposure to opioids, sedatives, or psychotropics, and evaluated factors that predicted medication exposure and drug exposure patterns over time. Result Of the 17 159 infants admitted to a NICU, 3 032 (18%) were exposed to at least one drug of interest. Lower gestational age (aOR 0.82 per week, 95% CI 0.81–0.83) and White race (aOR 1.28, 95% CI 1.18–1.39) were associated with exposure (both p < 0.001). The rates of dexmedetomidine, ketamine, clonidine, and fentanyl exposure increased over time. Lorazepam, midazolam, and pentobarbital rates decreased. Conclusion Neuroactive medication use has changed over time. Exposure is most common in premature infants, underscoring the urgent need for clinical trials to establish their safety and efficacy.
- Open Access
- 25 June 2026
- Published by Springer Nature in Journal of Perinatology
Sedative use in infants with grade 3 bronchopulmonary dysplasia (BPD) and associations with neurodevelopmental therapies
Background/Objectives: To characterize sedative and analgesic use in NICU patients with grade 3 bronchopulmonary dysplasia (BPD) in relation to respiratory support and neurodevelopmental therapies. Subjects/Methods: Point-prevalence survey across 22 NICUs of infants <24 months corrected age with grade 3 BPD who had never been discharged. Exclusions included recent sepsis, tracheostomy, or major surgery. Data were analyzed descriptively. Results: Among 141 infants, 97 (69%) received ≥1 sedative within 48 hours; 73 (75%) received multiple (mean 2.8 ± 1.6). Alpha-agonizts (n=67) and benzodiazepines (n=65) were most common, with 27 infants receiving an alpha-agonist, opioid, and benzodiazepine combination. Sedative exposure and medication count correlated with higher respiratory support (p<0.001) and FiO₂ (r=0.28, p<0.01). Sedation was associated with fewer completed therapy sessions (z=3.3, p<0.001). Conclusion: Sedation and polypharmacy were frequent among infants with severe BPD and linked to reduced therapy participation, highlighting the need to assess prescribing rationale and neurodevelopmental impacts.
- 25 June 2026
- Published by Springer Nature in Journal of Perinatology
Open AccessSedative use in infants with grade 3 bronchopulmonary dysplasia (BPD) and associations with neurodevelopmental therapies
Background/Objectives: To characterize sedative and analgesic use in NICU patients with grade 3 bronchopulmonary dysplasia (BPD) in relation to respiratory support and neurodevelopmental therapies. Subjects/Methods: Point-prevalence survey across 22 NICUs of infants <24 months corrected age with grade 3 BPD who had never been discharged. Exclusions included recent sepsis, tracheostomy, or major surgery. Data were analyzed descriptively. Results: Among 141 infants, 97 (69%) received ≥1 sedative within 48 hours; 73 (75%) received multiple (mean 2.8 ± 1.6). Alpha-agonizts (n=67) and benzodiazepines (n=65) were most common, with 27 infants receiving an alpha-agonist, opioid, and benzodiazepine combination. Sedative exposure and medication count correlated with higher respiratory support (p<0.001) and FiO₂ (r=0.28, p<0.01). Sedation was associated with fewer completed therapy sessions (z=3.3, p<0.001). Conclusion: Sedation and polypharmacy were frequent among infants with severe BPD and linked to reduced therapy participation, highlighting the need to assess prescribing rationale and neurodevelopmental impacts.
- 29 May 2024
- Published by Springer Nature in Journal of Perinatology
- Vol. 44 (11) , 1630-1634
Method of home tube feeding and 2–3-year neurodevelopmental outcome
Objective To describe the Bayley Scales of Infant Development 3rd Edition (Bayley-III) of infants discharged home receiving tube feeds. Study design Retrospective review of infants discharged with nasogastric or gastrostomy tube feeds and completed a Bayley-III assessment at 2–3-years of age through a neonatal follow-up program. Results were reported using descriptive statistics. Results Of infants discharged with nasogastric feeds, median Bayley-III scores were in the low-average to average range, and full oral feeds were achieved in 75%. Of infants discharged with gastrostomy tube feeds, median Bayley-III scores were in the extremely low range, and full oral feeds were achieved in 36%. Our data set did not demonstrate a distinct patient demographic that correlated to the type of feeding tube at discharge. Conclusion Neurodevelopmental outcome at 2–3 years does not appear to be negatively impacted by the decision to discharge an infant from the NICU with home NG feedings.
- 29 May 2024
- Published by Springer Nature in Journal of Perinatology
- Vol. 44 (11) , 1630-1634
Method of home tube feeding and 2–3-year neurodevelopmental outcome
Objective To describe the Bayley Scales of Infant Development 3rd Edition (Bayley-III) of infants discharged home receiving tube feeds. Study design Retrospective review of infants discharged with nasogastric or gastrostomy tube feeds and completed a Bayley-III assessment at 2–3-years of age through a neonatal follow-up program. Results were reported using descriptive statistics. Results Of infants discharged with nasogastric feeds, median Bayley-III scores were in the low-average to average range, and full oral feeds were achieved in 75%. Of infants discharged with gastrostomy tube feeds, median Bayley-III scores were in the extremely low range, and full oral feeds were achieved in 36%. Our data set did not demonstrate a distinct patient demographic that correlated to the type of feeding tube at discharge. Conclusion Neurodevelopmental outcome at 2–3 years does not appear to be negatively impacted by the decision to discharge an infant from the NICU with home NG feedings.
- Open Access
- 25 November 2023
- Published by Springer Nature in Research Square
Method of Home Tube Feeding and 2–3-year Neurodevelopmental Outcome
Objective: To describe the Bayley Scales of Infant Development 3rd Edition (Bayley-III) of infants discharged home receiving tube feeds Study Design: Retrospective review of infants discharged with nasogastric or gastrostomy tube feeds and completed a Bayley-III assessment at 2-3-years of age through a neonatal follow-up program. Results were reported using descriptive statistics. Results: Of infants discharged with nasogastric feeds, median Bayley-III scores were in the low-average to average range and full oral feeds were achieved in 75%. Of infants discharged with gastrostomy tube feeds, median Bayley-III scores were in the extremely low range and full oral feeds were achieved in 36%. Our data set did not demonstrate a distinct patient demographic that correlated to the type of feeding tube at discharge. Conclusion: Neurodevelopmental outcome at 2–3 years does not appear to be negatively impacted by the decision to discharge an infant from the NICU with home NG feedings.
- 25 November 2023
- Published by Springer Nature in Research Square
Open AccessMethod of Home Tube Feeding and 2–3-year Neurodevelopmental Outcome
Objective: To describe the Bayley Scales of Infant Development 3rd Edition (Bayley-III) of infants discharged home receiving tube feeds Study Design: Retrospective review of infants discharged with nasogastric or gastrostomy tube feeds and completed a Bayley-III assessment at 2-3-years of age through a neonatal follow-up program. Results were reported using descriptive statistics. Results: Of infants discharged with nasogastric feeds, median Bayley-III scores were in the low-average to average range and full oral feeds were achieved in 75%. Of infants discharged with gastrostomy tube feeds, median Bayley-III scores were in the extremely low range and full oral feeds were achieved in 36%. Our data set did not demonstrate a distinct patient demographic that correlated to the type of feeding tube at discharge. Conclusion: Neurodevelopmental outcome at 2–3 years does not appear to be negatively impacted by the decision to discharge an infant from the NICU with home NG feedings.
- 2 August 2023
- Published by Springer Nature in Journal of Perinatology
- Vol. 43 (10) , 1321-1329
A quality improvement initiative for neonatal hypoglycemia screening and management in a level III neonatal intensive care unit
Objective To bring screening and management of neonatal hypoglycemia in alignment with the 2011 AAP hypoglycemia clinical report Methods A multidisciplinary team developed a quality improvement initiative for neonatal hypoglycemia in neonates ≥35 weeks gestational age in a Level III neonatal intensive care unit between July 2020 and December 2021. A key driver diagram identified interventions for plan-do-study-act testing with corresponding measures to implement a hypoglycemia management protocol and improve adherence to AAP guidelines. Results Time to first blood glucose measurement increased from 49.8 to 122.7 min of life and time to first enteral feed decreased from 14.2 to 3.6 h of life. Neonates receiving intravenous dextrose decreased from 97.1 to 24.7% and discharge rates as a mother-neonate dyad increased from 35 to 62.4%. Conclusions Adherence to the AAP guidelines improved during testing and implementation of a hypoglycemia protocol and was associated with an increased mother-neonate dyad discharge rate.
- 2 August 2023
- Published by Springer Nature in Journal of Perinatology
- Vol. 43 (10) , 1321-1329
A quality improvement initiative for neonatal hypoglycemia screening and management in a level III neonatal intensive care unit
Objective To bring screening and management of neonatal hypoglycemia in alignment with the 2011 AAP hypoglycemia clinical report Methods A multidisciplinary team developed a quality improvement initiative for neonatal hypoglycemia in neonates ≥35 weeks gestational age in a Level III neonatal intensive care unit between July 2020 and December 2021. A key driver diagram identified interventions for plan-do-study-act testing with corresponding measures to implement a hypoglycemia management protocol and improve adherence to AAP guidelines. Results Time to first blood glucose measurement increased from 49.8 to 122.7 min of life and time to first enteral feed decreased from 14.2 to 3.6 h of life. Neonates receiving intravenous dextrose decreased from 97.1 to 24.7% and discharge rates as a mother-neonate dyad increased from 35 to 62.4%. Conclusions Adherence to the AAP guidelines improved during testing and implementation of a hypoglycemia protocol and was associated with an increased mother-neonate dyad discharge rate.
- 8 January 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (3) , 348-353
Blanket temperature during therapeutic hypothermia and outcomes in hypoxic ischemic encephalopathy
Objective Determine whether blanket temperatures during therapeutic hypothermia (TH) are associated with 18–22 month outcomes for infants with hypoxic ischemic encephalopathy (HIE). Study design Retrospective cohort study of 181 infants with HIE who received TH in two randomized trials within the Neonatal Research Network. We defined summative blanket temperature constructs and evaluated for association with a primary composite outcome of death or moderate/ severe disability at 18–22 months. Results Each 0.5 °C above 33.5 °C in the mean of the highest quartile blanket temperature was associated with a 52% increase in the adjusted odds of death/ disability (aOR 1.52, 95% CI 1.09–2.11). Having >8 consecutive blanket temperatures above 33.5 °C rendered an aOR of death/disability of 5.04 in the first 24 h (95% CI 1.54–16.6) and 6.92 in the first 48 h (95% CI 2.20–21.8) of TH. Conclusions Higher blanket temperature during TH may be an early, clinically useful biomarker of HIE outcome.
- 8 January 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (3) , 348-353
Blanket temperature during therapeutic hypothermia and outcomes in hypoxic ischemic encephalopathy
Objective Determine whether blanket temperatures during therapeutic hypothermia (TH) are associated with 18–22 month outcomes for infants with hypoxic ischemic encephalopathy (HIE). Study design Retrospective cohort study of 181 infants with HIE who received TH in two randomized trials within the Neonatal Research Network. We defined summative blanket temperature constructs and evaluated for association with a primary composite outcome of death or moderate/ severe disability at 18–22 months. Results Each 0.5 °C above 33.5 °C in the mean of the highest quartile blanket temperature was associated with a 52% increase in the adjusted odds of death/ disability (aOR 1.52, 95% CI 1.09–2.11). Having >8 consecutive blanket temperatures above 33.5 °C rendered an aOR of death/disability of 5.04 in the first 24 h (95% CI 1.54–16.6) and 6.92 in the first 48 h (95% CI 2.20–21.8) of TH. Conclusions Higher blanket temperature during TH may be an early, clinically useful biomarker of HIE outcome.
- 13 May 2021
- Published by Springer Nature in Journal of Perinatology
- Vol. 41 (6) , 1339-1346
Darbepoetin as a neuroprotective agent in mild neonatal encephalopathy: a randomized, placebo-controlled, feasibility trial
Objective To assess the feasibility and safety of one dose of Darbepoetin alpha (Darbe) administered to neonates ≥34 weeks with mild neonatal encephalopathy (NE). Methods Randomized, masked, placebo-controlled study including neonates ≥34 weeks gestation with mild NE. Neonates were randomized to receive one dose of Darbe (10 μg/kg IV) or placebo. Clinical and laboratory maternal and newborn data were collected. The Bayley Scales of Infant and Toddler Development, third edition (Bayley-III) and a standardized neurological examination at 8–12 months of corrected age were assessed. Results There were no differences in baseline characteristics of the 21 infants randomized (9 Darbe, 12 placebo). Adverse events were not reported at any time. Bayley-III scores were average in both Darbe and placebo groups. Conclusion This study demonstrates that a randomized, masked, placebo-controlled trial is safe and feasible. A large, randomized trial is warranted to assess the effect of Darbe in this population.
- 13 May 2021
- Published by Springer Nature in Journal of Perinatology
- Vol. 41 (6) , 1339-1346
Darbepoetin as a neuroprotective agent in mild neonatal encephalopathy: a randomized, placebo-controlled, feasibility trial
Objective To assess the feasibility and safety of one dose of Darbepoetin alpha (Darbe) administered to neonates ≥34 weeks with mild neonatal encephalopathy (NE). Methods Randomized, masked, placebo-controlled study including neonates ≥34 weeks gestation with mild NE. Neonates were randomized to receive one dose of Darbe (10 μg/kg IV) or placebo. Clinical and laboratory maternal and newborn data were collected. The Bayley Scales of Infant and Toddler Development, third edition (Bayley-III) and a standardized neurological examination at 8–12 months of corrected age were assessed. Results There were no differences in baseline characteristics of the 21 infants randomized (9 Darbe, 12 placebo). Adverse events were not reported at any time. Bayley-III scores were average in both Darbe and placebo groups. Conclusion This study demonstrates that a randomized, masked, placebo-controlled trial is safe and feasible. A large, randomized trial is warranted to assess the effect of Darbe in this population.
- 22 September 2020
- Published by Springer Nature in Journal of Perinatology
- Vol. 40 (12) , 1828-1833
The impact of the Baby Friendly Hospital Initiative on neonatal hypoglycemia
Objective To assess Neonatal Intensive Care Unit (NICU) admissions for hypoglycemia after the introduction of the Baby Friendly Hospital Initiative (BFHI), followed by implementation of American Academy of Pediatrics recommended hypoglycemia guidelines. Study design Retrospective review of NICU admissions for hypoglycemia. Eligible subjects were healthy infants >35 weeks gestation transferred to a NICU for hypoglycemia. Infants admitted with other pathologies were excluded. NICU admissions from 3 different 18-month epochs (1 = pre-BFHI; 2 = post-BFHI; 3 = post-BFHI+hypoglycemia guidelines) were compared. Results After implementation of BFHI there was a statistically significant increase in admissions for hypoglycemia (Epoch 2 = 1.23% vs Epoch 1 = 0.55%, p < 0.001). Followed by a decrease in admissions after the implementation of hypoglycemia guidelines (Epoch 2 = 1.23% vs Epoch 3 = 0.76%, p = 0.03). Conclusion NICU admissions for hypoglycemia increased with the BFHI. Hypoglycemia guidelines decreased NICU admissions, but not to the pre-BFHI baseline.
- 22 September 2020
- Published by Springer Nature in Journal of Perinatology
- Vol. 40 (12) , 1828-1833
The impact of the Baby Friendly Hospital Initiative on neonatal hypoglycemia
Objective To assess Neonatal Intensive Care Unit (NICU) admissions for hypoglycemia after the introduction of the Baby Friendly Hospital Initiative (BFHI), followed by implementation of American Academy of Pediatrics recommended hypoglycemia guidelines. Study design Retrospective review of NICU admissions for hypoglycemia. Eligible subjects were healthy infants >35 weeks gestation transferred to a NICU for hypoglycemia. Infants admitted with other pathologies were excluded. NICU admissions from 3 different 18-month epochs (1 = pre-BFHI; 2 = post-BFHI; 3 = post-BFHI+hypoglycemia guidelines) were compared. Results After implementation of BFHI there was a statistically significant increase in admissions for hypoglycemia (Epoch 2 = 1.23% vs Epoch 1 = 0.55%, p < 0.001). Followed by a decrease in admissions after the implementation of hypoglycemia guidelines (Epoch 2 = 1.23% vs Epoch 3 = 0.76%, p = 0.03). Conclusion NICU admissions for hypoglycemia increased with the BFHI. Hypoglycemia guidelines decreased NICU admissions, but not to the pre-BFHI baseline.
- 3 September 2019
- Published by Wiley in Transfusion
- Vol. 59 (10) , 3113-3119
Evaluating emergency‐release blood transfusion of newborn infants at the Intermountain Healthcare hospitals
BACKGROUND: An emergency‐release blood transfusion (ERBT) protocol (uncrossmatched type O‐negative red blood cells, AB plasma, AB platelets) is critical for neonatology practice. However, few reports of emergency transfusions are available. We conducted an ERBT quality improvement project as a basis for progress.STUDY DESIGN AND METHODS: For each ERBT in the past 8 years, we logged indications, products, locations and timing of the transfusions, and outcomes.RESULTS: One hundred forty‐nine ERBTs were administered; 42% involved a single blood product, and 58% involved two or more. The incidence was 6.25 ERBT per 10,000 live births, with a higher rate (9.52 ERBT/10,000) in hospitals with a Level 3 neonatal intensive care unit (NICU) (p < 0.001). Seventy percent of ERBTs were administered in a NICU and 30% in a delivery room, operating room, or emergency department. Indications were abruption/previa (32.2%), congenital anemia (i.e., fetomaternal hemorrhage; 15.4%), umbilical cord accident (i.e., velamentous insertion; 15.0%), and bleeding/coagulopathy (12.8%). Fifty‐eight percent of those with hemorrhage before birth did not have a hemoglobin value reported on the umbilical cord gas; thus, anemia was not recognized initially. None of the 149 ERBTs were administered using a blood warmer. The mortality rate of recipients was 35%.CONCLUSION: Based on our findings, we recommend including a hemoglobin value with every cord blood gas after emergency delivery to rapidly identify fetal anemia. We also discuss two potential improvements for future testing: 1) the use of a warming device for massive transfusion of neonates and 2) the use of low‐titer group O cold‐stored whole blood for massive hemorrhage in neonates.
- 3 September 2019
- Published by Wiley in Transfusion
- Vol. 59 (10) , 3113-3119
Evaluating emergency‐release blood transfusion of newborn infants at the Intermountain Healthcare hospitals
BACKGROUND: An emergency‐release blood transfusion (ERBT) protocol (uncrossmatched type O‐negative red blood cells, AB plasma, AB platelets) is critical for neonatology practice. However, few reports of emergency transfusions are available. We conducted an ERBT quality improvement project as a basis for progress.STUDY DESIGN AND METHODS: For each ERBT in the past 8 years, we logged indications, products, locations and timing of the transfusions, and outcomes.RESULTS: One hundred forty‐nine ERBTs were administered; 42% involved a single blood product, and 58% involved two or more. The incidence was 6.25 ERBT per 10,000 live births, with a higher rate (9.52 ERBT/10,000) in hospitals with a Level 3 neonatal intensive care unit (NICU) (p < 0.001). Seventy percent of ERBTs were administered in a NICU and 30% in a delivery room, operating room, or emergency department. Indications were abruption/previa (32.2%), congenital anemia (i.e., fetomaternal hemorrhage; 15.4%), umbilical cord accident (i.e., velamentous insertion; 15.0%), and bleeding/coagulopathy (12.8%). Fifty‐eight percent of those with hemorrhage before birth did not have a hemoglobin value reported on the umbilical cord gas; thus, anemia was not recognized initially. None of the 149 ERBTs were administered using a blood warmer. The mortality rate of recipients was 35%.CONCLUSION: Based on our findings, we recommend including a hemoglobin value with every cord blood gas after emergency delivery to rapidly identify fetal anemia. We also discuss two potential improvements for future testing: 1) the use of a warming device for massive transfusion of neonates and 2) the use of low‐titer group O cold‐stored whole blood for massive hemorrhage in neonates.